Literature DB >> 7553000

Potent effects of low levels of MHC class II-associated invariant chain on CD4+ T cell development.

M F Naujokas1, L S Arneson, B Fineschi, M E Peterson, S Sitterding, A T Hammond, C Reilly, D Lo, J Miller.   

Abstract

Invariant chain (Ii)-negative mice exhibit defects in MHC class II assembly and transport that results in reduced levels of surface class II, altered antigen presentation, and inefficient positive selection of CD4+ T cells. Many CD4+ T cells that do mature in Ii-negative mice express a cell surface phenotype consistent with aberrant positive selection or peripheral activation. Reconstitution of these mice with low levels of either the p31 or p41 form of Ii does not restore transport of the bulk of class II or class II surface expression, but surprisingly does restore positive selection as measured by numbers and surface phenotype of CD4+ T cells. Thus, an Ii-dependent process, independent of effects on class II surface density, appears to be required for normal positive selection of CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553000     DOI: 10.1016/1074-7613(95)90120-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  12 in total

1.  Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands.

Authors:  W C Kieper; S C Jameson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.

Authors:  Xuerong Shi; Lin Leng; Tian Wang; Wenkui Wang; Xin Du; Ji Li; Courtney McDonald; Zun Chen; James W Murphy; Elias Lolis; Paul Noble; Warren Knudson; Richard Bucala
Journal:  Immunity       Date:  2006-10       Impact factor: 31.745

Review 3.  Thymic stromal cell specialization and the T-cell receptor repertoire.

Authors:  D Lo; C R Reilly; L C Burkly; J DeKoning; T M Laufer; L H Glimcher
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

4.  Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1.

Authors:  James D Swant; Beatriz E Rendon; Marc Symons; Robert A Mitchell
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

5.  The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice.

Authors:  R J Wright; E K Bikoff; B Stockinger
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

6.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

7.  Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors.

Authors:  Vincent A Carlier; Luc VanderElst; Wim Janssens; Marc G Jacquemin; Jean-Marie R Saint-Remy
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

8.  Analysis of 10,000 ESTs from lymphocytes of the cynomolgus monkey to improve our understanding of its immune system.

Authors:  Wei-Hua Chen; Xue-Xia Wang; Wei Lin; Xiao-Wei He; Zhen-Qiang Wu; Ying Lin; Song-Nian Hu; Xiao-Ning Wang
Journal:  BMC Genomics       Date:  2006-04-18       Impact factor: 3.969

9.  Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells.

Authors:  P Pierre; I Shachar; D Matza; E Gatti; R A Flavell; I Mellman
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

10.  MIF signal transduction initiated by binding to CD74.

Authors:  Lin Leng; Christine N Metz; Yan Fang; Jing Xu; Seamas Donnelly; John Baugh; Thomas Delohery; Yibang Chen; Robert A Mitchell; Richard Bucala
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.